Core Viewpoint - Jincheng Pharmaceutical's subsidiary, Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its injectable Cefuroxime Sodium product, indicating a significant advancement in the company's product portfolio and market potential [1] Group 1 - The approved product, injectable Cefuroxime Sodium, is a proprietary drug developed by the company, marketed under the brand name "Lifule" [1] - The drug is produced using technology and raw materials sourced from ACS DOBFAR S.P.A, highlighting a collaboration that may enhance production quality and efficiency [1] - Cefuroxime Sodium is indicated for treating infections caused by bacteria sensitive to the drug, including respiratory, ENT, urinary tract, skin and soft tissue infections, sepsis, meningitis, and bone and joint infections [1] Group 2 - The product is also indicated for the prevention of infections during surgical procedures, such as abdominal, pelvic, orthopedic, cardiac, pulmonary, esophageal, vascular, and total joint replacement surgeries, expanding its application in clinical settings [1]

Core Viewpoint - The company announced that its subsidiary, Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd., received a notification from the National Medical Products Administration regarding the approval of a supplemental application for injectable Cefuroxime Sodium, which is a proprietary drug of the company [1] Group 1 - The approved drug is indicated for infections caused by various bacteria and can be used for infection prevention in surgical procedures [1] - The revision of quality standards is expected to positively impact product quality [1] - Sales of the drug may be influenced by policy and market conditions, indicating potential risks for investors [1]

证券代码：300233 证券简称：金城医药 公告编号：2026-002 山东金城医药集团股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 产品 名称 剂 型 注册 分类 规格 包装 规格 原药品批 准文号 上市许 可持有 人 生产 企业 审批结论 注 射 用 头 孢 呋 辛 钠 注 射 剂 化学 药品 0.5g （1） 每盒 1 瓶。 （2） 每盒 10 瓶。 国药准字 H20065669 金城 金素 金城 金素 根据《中华人民共和国 药品管理法》及有关规 定，经审查，本品此次 申请事项符合药品注册 的有关要求，批准本品 注册标准的变更。质量 标准照所附执行。其他 照原批准内容执行。相 关变更应自获批之日起 6 个月内实施。 0.75 g 国药准字 H20065670 1.5g 国药准字 H20065672 一、药品基本情况 积极意义。药品销售受国家政策、市场环境等不确定因素的影响，敬请广大投资 者注意风险，理性投资。 特此公告。 山东金城医药集团股份有限公司董事会 关于子公司收到药品补充申请批准通知书的公告 山东金城医药集团股份有限公司之控股子公 ...

Group 1 - The core viewpoint of the news is that Jincheng Pharmaceutical's stock has increased by 5.37%, reaching a price of 15.88 yuan per share, with a trading volume of 1.81 billion yuan and a turnover rate of 3.15%, resulting in a total market capitalization of 60.96 billion yuan [1] - Jincheng Pharmaceutical, established on January 12, 2004, and listed on June 22, 2011, is located in Zibo City, Shandong Province. The company specializes in the research, production, and sales of pharmaceutical intermediates, active pharmaceutical ingredients, and finished formulations [1] - The revenue composition of Jincheng Pharmaceutical includes: formulation products at 34.59%, other pharmaceutical and chemical products at 26.61%, cephalosporin side-chain active ester series products at 21.88%, and biopharmaceuticals and specialty active pharmaceutical ingredients at 16.92% [1] Group 2 - Among the top circulating shareholders of Jincheng Pharmaceutical, a fund under the Fortune Fund ranks as a significant stakeholder. The Fortune Precision Medical Flexible Allocation Mixed A Fund (005176) entered the top ten circulating shareholders in the third quarter, holding 4.961 million shares, which accounts for 1.33% of the circulating shares [2] - The Fortune Precision Medical Flexible Allocation Mixed A Fund has a current scale of 3.491 billion yuan, with a year-to-date return of 4.34%, ranking 4447 out of 8844 in its category. Over the past year, it has achieved a return of 40.91%, ranking 2780 out of 8091, and since its inception, it has returned 212.06% [2] Group 3 - The fund manager of the Fortune Precision Medical Flexible Allocation Mixed A Fund is Zhao Wei, who has been in the position for 8 years and 218 days. The total asset scale of the fund is 9.845 billion yuan, with the best return during his tenure being 190.69% and the worst return being -13.15% [3]

Group 1 - The core viewpoint of the news is that Jincheng Pharmaceutical has seen a significant increase in its stock price, rising 5.03% to 15.86 CNY per share, with a total market capitalization of 6.088 billion CNY [1] - Jincheng Pharmaceutical has experienced a cumulative increase of 4.86% over the past three days, indicating positive market sentiment [1] - The company, established in 2004 and listed in 2011, specializes in the research, production, and sales of pharmaceutical intermediates, active pharmaceutical ingredients, and finished formulations [1] Group 2 - According to data, Guotai Fund holds a significant position in Jincheng Pharmaceutical through its fund Guotai Health Stock A, which has 932,200 shares, accounting for 5.4% of the fund's net value [2] - The fund has generated a floating profit of approximately 708,500 CNY today, with a total floating profit of 652,500 CNY during the three-day price increase [2] - Guotai Health Stock A has a total scale of 303 million CNY and has achieved a year-to-date return of 13.23% [2]

证券代码：300233 证券简称：金城医药 公告编号：2026-001 山东金城医药集团股份有限公司 关于控股股东部分股份质押展期的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司（以下简称"公司"）于 2026 年 1 月 12 日接到控 股股东淄博金城实业投资股份有限公司（以下简称"金城实业"）的通知，其持有的本 公司部分股份办理质押展期业务，具体情况如下： | 是否为控 | 本次 | 本次质 | 占公 | 是否 | 股股东或 | 占其所 | 是否 | 质押 | 展期 | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 押展期 | 司总 | 为补 | 质押起 | 质权 | 质押 | 第一大股 | 持股份 | 为限 | 到期 | 后质 | 名称 | ...

Group 1 - The company, Jincheng Pharmaceutical (300233), stated on an interactive platform that if there is a share repurchase plan, it will fulfill its information disclosure obligations according to relevant regulations [1]

Core Viewpoint - Jincheng Pharmaceutical (300233.SZ) is facing multiple challenges, including tax payment issues, stock manipulation by its actual controller Zhao Yeqing, and declining financial performance, raising concerns about the company's future stability and management effectiveness [2][9]. Group 1: Tax Issues - Jincheng Jinsu Pharmaceutical Co., Ltd. and its subsidiary Guangdong Landu Pharmaceutical Co., Ltd. were required to pay a total of 21.5968 million yuan in back taxes and penalties due to tax issues from 2017 to 2018 [3]. - The tax payments have been completed as of the announcement date, and a supplementary agreement was signed to revise tax liability clauses related to the tax recovery [5]. Group 2: Stock Manipulation - Zhao Yeqing, the actual controller of Jincheng Pharmaceutical, was involved in stock manipulation from August 2017 to February 2020, using 104 accounts to trade the company's stock, which led to a fine and a four-year market ban [7][8]. - The manipulation involved significant trading activity, with 1.19 billion shares bought and 1.07 billion shares sold, resulting in a loss of 7.392 million yuan for the involved accounts [8]. Group 3: Financial Performance - Jincheng Pharmaceutical's financial performance has been declining, with a revenue of 35.38 billion yuan in 2023, a growth rate of only 0.93%, and a net profit decrease of 36.09% to 1.75 billion yuan [9]. - In the first three quarters of 2025, the company reported a revenue of 19.32 billion yuan, down 23.19%, and a net profit of 31.5771 million yuan, down 79.1% [9]. - The company experienced a significant decline in its gross margin to 36.23%, a decrease of 3.9 percentage points, and a net margin of 1.74%, down 4.71 percentage points compared to the previous year [9].

证券代码：300233 证券简称：金城医药 公告编号：2025-089 山东金城医药集团股份有限公司 检查范围：原料药乳糖酸红霉素，一车间，乳糖酸红霉素生产线 关于子公司收到药品 GMP 符合性检查告知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司全资子公司北京金城泰尔制药有限公司（以 下简称"金城泰尔"）收到北京市药品监督管理局核准签发的《药品 GMP 符合性 检查告知书》（京药监药 GMP〔2025〕020107），其申报的乳糖酸红霉素原料药 已通过《药品生产质量管理规范（2010 年修订）》符合性检查（以下简称"GMP 符合性检查"）。现将有关情况公告如下： 一、《药品 GMP 符合性检查告知书》相关信息 企业名称：北京金城泰尔制药有限公司 检查地址：河北省沧州市临港经济技术开发区西区北京医药产业园经五路以 东纬二路以北 检查时间：2025 年 10 月 28 日至 10 月 31 日 检查结论：根据本次检查情况，经审查，该企业此次检查范围符合《药品生 产质量管理规范 (2010 年修订) 》和附录要求。 二、产品 ...

Core Viewpoint - Jincheng Pharmaceutical's subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received the GMP compliance inspection notice for the active pharmaceutical ingredient Mirabegron, allowing for domestic production and sales [1] Group 1: Company Developments - The approval from the Beijing Drug Administration signifies that the Mirabegron active pharmaceutical ingredient has passed the GMP compliance inspection, which is based on the 2010 revised Drug Production Quality Management Standards [1] - This achievement enhances the variety of products offered by the company and is expected to improve its competitiveness in the chemical raw material drug sector [1] - Jincheng Tail will proceed with production in accordance with relevant requirements and market demand [1]